Loading...
•
Dec 31, 2019
EyePoint Pharmaceuticals Q4 2019 Earnings Report
EyePoint Pharmaceuticals experienced commercial momentum with increased customer reception and adoption of DEXYCU and YUTIQ, resulting in strong customer demand and sales growth in Q4 2019.
Key Takeaways
EyePoint Pharmaceuticals reported total revenues of $8.6 million for Q4 2019, driven by net product revenues of $7.9 million from DEXYCU and YUTIQ. Customer demand for DEXYCU and YUTIQ increased significantly compared to Q3 2019. The company is advancing EYP-1901 towards clinical development and expects continued customer demand growth in 2020.
Total revenues reached $8.6 million in Q4 2019.
Net product revenues were $7.9 million in Q4 2019, with $4.8 million from YUTIQ and $3.1 million from DEXYCU.
Customer demand for DEXYCU and YUTIQ increased 111% and 59%, respectively, compared to Q3 2019.
EYP-1901 is advancing toward clinical development as a potential treatment for wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...